JPMorgan analyst Rachel Vatnsdal lowered the firm’s price target on 10x Genomics (TXG) to $12 from $14 and keeps a Neutral rating on the shares ...

Stifel lowered the firm’s price target on 10x Genomics (TXG) to $18 from $21 and keeps a Buy rating on the shares. The funding environment ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.

The top five meme coins with 10x potential are gaining attention, especially during this market downturn, as investors look ...

Hop across to the best casinos and play the 333 Jolly Fat Frogs POWER COMBO online slot. It’s a bright and cheerful slot from ...

CEO Serge Saxonov, PhD, says provider of single cell, spatial, and in situ instruments expects to see benefits from sales reorganization and grow base of industry users.

For the quarter ended December 2024, 10x Genomics (TXG) reported revenue of $165.02 million, down 10.3% over the same period last year. EPS came in at -$0.40, compared to -$0.41 in the year-ago ...

As of 2023 year-end, the firm had $1.2 billion of debt, $1.6 billion of cash and cash equivalents, and $1.5 billion of deferred taxes that are largely related to its Sartorius investment. We forecast ...

NEW BRAUNFELS, Texas, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Nomad Internet, a leader in providing high-speed internet solutions for rural America, has announced breakthrough results from a rigorous ...

LyondellBasell's strong dividend track record and a 7% yield make it attractive for dividend investors, despite recent stock ...

Once bogged down by balance sheet stress and sluggish growth, many government-owned companies now stand on a firmer footing, ...

Palantir trades at valuations such that the stock still looks richly valued even after hyperbolic growth in its business.